MannKind director exercises RSUs, sells shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MannKind Corp director Steven B. Binder reported multiple equity transactions. On July 15, 2026, a performance RSU award granted in 2023 vested at 83% of target, delivering 93,790 shares and forfeiting 19,210. Shares totaling 24,395 were withheld to cover taxes. On July 17, 2026, he sold 52,485 shares of common stock at a weighted average price of $4.06, in open-market transactions under a Rule 10b5-1 plan established December 2, 2025. After these transactions, he directly holds 824,918 shares of MannKind common stock.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, $0.01 Par Value F4, F3 | 52,485 | $4.06 | $213K |
| Exercise | Performance Restricted Stock Unit F5, F1 | 93,790 | $0.00 | $0.00 |
| Exercise | Common Stock, $0.01 Par Value F1 | 93,790 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock, $0.01 Par Value F2 | 15,688 | $4.09 | $64K |
| Exercise Price or Tax Liability | Common Stock, $0.01 Par Value F2 | 4,073 | $4.09 | $17K |
| Exercise Price or Tax Liability | Common Stock, $0.01 Par Value F2 | 4,634 | $4.09 | $19K |
Footnotes (5)
- F1. A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
- F2. Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
- F3. Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
- F4. The weighted average sales price of the reported transaction was $4.06 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Key Figures
Key Terms
Rule 10B5-1 Plan regulatory
Performance Restricted Stock Unit financial
Russell 3000 Pharmaceutical & Biotechnology Index financial
withholding securities financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MannKind (MNKD) director Steven B. Binder report in this Form 4?
What performance conditions led to Steven B. Binder’s RSU vesting at MannKind (MNKD)?
What are Steven B. Binder’s MannKind (MNKD) holdings after these transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.